Edition:
India

John Miller

Roche's $4.3 billion Spark bid delayed again amid U.S., UK scrutiny

10 Jun 2019

ZURICH Swiss drugmaker Roche's $4.3 billion takeover of U.S. gene therapy specialist Spark Therapeutics has been pushed back again, possibly beyond the first half, as regulators continue to scrutinize the deal for its effect on competition.

Roche's $4.3 bln Spark bid delayed again amid U.S., UK scrutiny

10 Jun 2019

ZURICH, June 10 Swiss drugmaker Roche's $4.3 billion takeover of U.S. gene therapy specialist Spark Therapeutics has been pushed back again, possibly beyond the first half, as regulators continue to scrutinize the deal for its effect on competition.

France's Sanofi bets on new CEO to drive sluggish drug sales

07 Jun 2019

ZURICH In veteran drug salesman Paul Hudson, Sanofi's 100,000-plus employees are getting a new chief executive who relishes a good commercial fight.

Novartis hopes Kisqali data will help narrow gap to blockbuster rival

01 Jun 2019

ZURICH Novartis has released data showing sharply improved overall survival rates for its breast cancer drug Kisqali, which the Swiss drugmaker hopes will help it chip away at the dominance of Pfizer's blockbuster Ibrance.

Swiss court blocks Italy's bid for possible da Vinci portrait

29 May 2019

ZURICH Switzerland's highest court has rejected Italy's request for the return of an oil painting attributed by some to Leonardo Da Vinci, ruling no Swiss laws were broken when the work was brought over the border.

Bombardier declines comment on Swiss train deal profitability

29 May 2019

ZURICH Bombardier delivered three double-decker trains to Switzerland this month for a total of 15, it said on Wednesday, but declined to comment after the Swiss rail boss said the company was losing money on the overdue contract.

Novartis $2 million gene therapy for rare disorder is world's most expensive drug

25 May 2019

ZURICH/NEW YORK, Swiss drugmaker Novartis on Friday won U.S. approval for its gene therapy Zolgensma for spinal muscular atrophy (SMA), the leading genetic cause of death in infants, and priced the one-time treatment at a record $2.125 million. | Video

World News